poisar

Stocks · News reference

Raymond James Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $39

Aug 14, 2026, 10:47 AMBenzinga Newsdesk

Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Outperform rating and announces Price Target of $39.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SGP
Source
benzinga
Observed
Aug 14, 2026, 10:47 AM
Checked
Aug 14, 2026, 10:47 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Jun 15, 2026, 12:00 PMNa

    SpyGlass Pharma Appoints Shannon Treviño as General Counsel

    SpyGlass Pharma, a late-stage biopharmaceutical company, announced the appointment of Shannon Treviño as general counsel. Treviño brings extensive legal experience from her previous role as General Counsel at Inari Medical, where she oversaw the company's $4.9 billion acquisition by Stryker. She will support SpyGlass's Phase 3 trials for its BIM-IOL System, a drug delivery device designed to treat glaucoma and ocular hypertension.

    Read original at globenewswire-inc
    SGPSYK